Cas9 protein mutant and application thereof in gene editing technology

By developing the Cas9 protein mutant Cas9M24 and corresponding vectors in Pichia, the CRISPR/Cas9 gene editing system was constructed, and the problems of insufficient efficacy and toxicity of natural Cas9 in Pichia were solved, achieving more efficient gene editing effects and Lower cytotoxicity, suitable for biomanufacturing and metabolic engineering.

CN118956820AActive Publication Date: 2024-11-15ACADEMY OF MILITARY MEDICAL SCIENCES +1
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202410571121.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-05-10
Publication Date
2024-11-15
Estimated Expiration
2044-05-10

AI Technical Summary

Technical Problem

The natural Cas9 protein cannot perform the best performance in Pichia yeast, resulting in poor gene editing effect and certain toxic effects, affecting species adaptability.

Method used

A Cas9 protein mutant Cas9M24, which has mutations of D276N, A421T, and A1184T, combined with pGAP-Cas9 vector and pTEF-gRNA vector, was developed to construct the CRISPR/Cas9 gene editing system in Pichia cerevisiae, and stable PCR screening was obtained through error-prone PCR screening. Sex and compatibility of Cas9 mutants.

Benefits of technology

The Cas9M24 mutant showed higher gene editing efficiency and stability in Pichia yeast, especially for the PAM motifs AGG and TGG, which increased by 10% compared with wild-type Cas9 and reduced cytotoxicity. Suitable for genetic engineering operations in yeast cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118956820A_ABST
    Figure CN118956820A_ABST
Patent Text Reader

Abstract

The invention provides a Cas9 protein mutant, a vector for expressing the Cas9 protein mutant and a method for performing gene editing by using the vector. The Cas9 protein mutant provided by the invention shows higher adaptability and gene editing efficiency than a wild type in pichia pastoris, and the editing probability of the Cas9 protein mutant to a target gene reaches 90% or above.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention discloses a protein mutant and gene editing technology. Background Art

[0002] Clustered regularly interspaced shortpalindromic repeats (CRISPR) / CRISPR-associated protein 9 (Cas9) is an efficient and precise gene editing technology that can introduce base insertions, deletions or substitutions at specific sites in the genome to correct harmful base mutations or destroy pathogenic genes. Compared with the other two base-level gene editing technologies, zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), the construction of the CRISPR / Cas9 system is simpler, more efficient and less expensive. When applied, the target gene can be programmed by simply changing the targeting sequence of the gRNA. It is widely used in the fields of cell gene modification, animal model construction, and high-throughput drug screening. The system consists of two parts: the Cas9 protein that can exert nucleic acid cleavage activity and the gRNA that can play a guiding role. Under the guidance of the gRNA, Cas9 reaches the designated site to perform cleavage activity, thereby achieving DNA chain breakage and gene destruction. The CRISPR / Cas9 system requires a short guanine-rich sequence, the protospacer-adjacent motif (PAM), to participate in the recognition / cutting activity, such as Streptococcus pyogenes Cas9 ( Streptococcus pyogenes The PAM sequence of Cas9 (SpCas9) is NGG.

[0003] The CRISPR / Cas9 system has been applied to a variety of organisms, but the natural Cas9 protein may have certain defects or toxic effects in different species. In order to achieve better species adaptability and better gene editing effects, the Cas9 protein can be modified for different organisms to obtain a potentially better CRISPR / Cas9 system for a certain species.

[0004] As an emerging exogenous protein expression system after Saccharomyces cerevisiae, Pichia pastoris is widely accepted for its advantages of high protein expression level, easy separation and purification, and glycosylation modification closer to higher organisms. The wild-type Cas9 sequence may not be able to exert its optimal performance in Pichia pastoris. The purpose of the present invention is to provide a Cas9 mutant adapted to Pichia pastoris through error-prone PCR, and to construct a CRISPR / Cas9 gene editing system on Pichia pastoris based on this Cas9 mutant, so as to provide a better gene editing tool for precise gene manipulation based on Pichia pastoris. Summary of the invention

[0005] Based on the above purpose, the present invention first provides a Cas9 protein mutant, which is a mutant having D276N, A421T, and A1184T in the sequence of SEQ ID NO.1. In the present invention, the mutant is named "Cas9M24".

[0006] Secondly, the present invention provides a polynucleotide encoding the above-mentioned Cas9 protein mutant. Based on the common sense of those skilled in the art, following the triplet code rule of protein coding, the same amino acid has different triplet nucleotide codes, so any polynucleotide capable of encoding the above-mentioned Cas9 protein mutant is within the scope of the polynucleotide defined by the present invention.

[0007] In a preferred embodiment, the sequence of the polynucleotide encoding the mutant having D276N, A421T, A1184T is shown as SEQ ID NO.4.

[0008] Third, the present invention provides a vector for expressing the above-mentioned Cas9 protein mutant, wherein the vector contains the above-mentioned polynucleotide encoding the Cas9 protein mutant. In a specific embodiment of the present invention, the vector is pGAP, and the vectors containing the Cas9 protein encoding gene in the present invention are collectively referred to as pGAP-Cas9s, including pGAP-Cas9 and pGAP-Cas9-M24.

[0009] Fourthly, the present invention provides a method for gene editing using the above-mentioned vector, the method comprising the following steps: (1) transforming the above-mentioned vector expressing the Cas9 protein mutant into a host bacterium to obtain a recombinant host bacterium in which the vector is integrated into the genome; (2) constructing a vector containing a gRNA targeting the target gene in the host bacteria genome in step (1), and transforming the vector into the recombinant host bacteria obtained in step (1); (3) Cultivate the recombinant host bacteria obtained in step (2) and screen the target gene to obtain edited positive host bacteria.

[0010] In a preferred embodiment, the host bacteria in step (1) is yeast.

[0011] In a more preferred embodiment, the yeast is the yeast GS115 strain.

[0012] In a specific embodiment of the present invention, the vector of the gRNA targeting the target gene in the host bacterial genome in step (2) is pTEF. The pTEF vector constructed in the present invention includes: PAS_ Chr4_0783 Gene, pTEF-GUT1-3 expression vector with PAM motif AGG, targeting Pichia pastoris genome PAS_ Chr4_0783 Gene, pTEF-GUT1-2 expression vector with PAM motif TGG, targeting Pichia pastoris genome PAS_chr1- 1_0483 Gene, pTEF-AC expression vector with PAM motif CGG, targeting Pichia pastoris genome PAS_chr1-4_0160 Gene, pTEF-H1 expression vector with PAM motif GGG. Each pTEF vector in the above technical scheme of the present invention is only used to verify the gene editing function of CRISPR-Cas9 protein mutants. Those skilled in the art can use other conventional gRNA vectors according to the requirements of gene editing purposes, design corresponding gRNA targeting sequences according to the target design principles and PAM sequence selection disclosed in the present invention, and complete the site-specific deletion of the target base of the target gene.

[0013] In a preferred embodiment, in the above method, the PAM motif at the 3' end of the target gene in step (2) is AGG or TGG.

[0014] In another preferred embodiment, the length of the gRNA target sequence in step (2) of the above method is 20 nt.

[0015] Finally, the present invention provides a gene editing kit, which includes a vector expressing the Cas9 protein mutant of the present invention, and a vector containing a gRNA targeting the target sequence of the target gene to be edited.

[0016] The CRISPR-Cas9M24 protein mutant provided by the present invention and the method for gene editing using the mutant are in Pichia pastoris, and this Cas9 mutant shows better stability and compatibility. It can better adapt to the physiological environment of Pichia pastoris and work in conjunction with other biological molecules in the cell to achieve more efficient gene editing. Although both wild-type CRISPR-Cas9 and CRISPR-Cas9M24 can cause base deletion or insertion in the target sequence. When the PAM motif is CGG and GGG, the gene editing efficiency of CRISPR-Cas9 and CRISPR-Cas9M24 is 90-100%, but when the PAM motif is AGG and TGG, the gene editing efficiency of CRISPR-Cas9M24 is as high as 100%, which is 10% higher than that of CRISPR-Cas9. The above results show that the CRISPR-Cas9M24 system is less toxic and inhibiting to yeast cells, and is more suitable for genetic engineering operations in yeast cells. And it is more suitable for site-directed editing of genes when the PAM motif is AGG and TGG.

[0017] Therefore, the excellent gene editing performance of the Cas9 mutant provided by the present invention in Pichia pastoris provides broad prospects for its application in the fields of biomanufacturing, metabolic engineering, drug development, etc. For example, the mutant can be used to accurately edit the metabolic pathway of Pichia pastoris to increase the yield of specific compounds or optimize production conditions. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 . Schematic diagram of the pGAP-Cas9 vector structure; Figure 2 pGAP-Cas9 plasmid restriction map and plasmid transformation strain PCR identification map, where A: pGAP-Cas9 Spe Ⅰ and XOt Ⅰ: Agarose gel electrophoresis results after double restriction digestion; B: Agarose gel electrophoresis results of colony PCR identification of positive clones after transformation of pGAP-Cas9 recombinant vector carrying different Cas9 mutants; Figure 3 . Sequencing comparison results of Cas9M24 mutant and Cas9 sequence; Figure 4 . Colony PCR identification results after pGAP-Cas9 and pGAP-Cas9M24 recombinant vectors were transformed into yeast strains; Figure 5 . Schematic diagram of the structures of four gRNA recombinant vectors targeting different PAM motifs Figure 6 . Colony PCR identification results after transformation of 4 gRNA recombinant vectors targeting different PAM motifs; Figure 7 . Sanger sequencing peak diagram of pTEF-GUT1-3, pTEF-GUT1-2, pTEF-AC, and pTEF-H1 recombinant vectors; Figure 8 . Screening results of positive clones after four different PAM motif gRNAs were transferred into CRISPR / Cas9 and CRISPR / Cas9-M24 strains; Fig. 9 . Statistical analysis of the number of positive clones obtained after four different PAM motif gRNAs were transferred into CRISPR / Cas9 and CRISPR / Cas9-M24 strains (n=3); Fig.10 . Sanger sequencing analysis after 4 gRNAs with different PAM motifs were introduced into CRISPR-Cas9 and CRISPR-Cas9M24 strains respectively. DETAILED DESCRIPTION

[0019] The present invention will be further described below in conjunction with specific embodiments, and the advantages and features of the present invention will become clearer as the description proceeds. However, these embodiments are merely exemplary and do not constitute any limitation on the scope of protection defined by the claims of the present invention.

[0020] Example 1. Screening of Cas9 mutants 1. Obtaining pGAP (commercially available)-Cas9 recombinant vectors, Cas9 variants, and cloning pGAP-Cas9 recombinant vectors carrying Cas9 variants The amino acid sequence of the CRISPR-associated protein Cas9 from Streptococcus pyogenes was obtained from NCBI (SEQ ID NO.1, GenBank: KT031982.1), and the pGAP-Cas9 recombinant vector is a Cas9 expression vector ( Figure 1 ), which initiates the transcriptional expression of Cas9 through the GAP promoter. This vector contains an ampicillin sequence for transformation and screening of prokaryotic bacteria. HIS The selection marker is used for transformation and screening of yeast strains. The NLS nuclear localization signal sequence (SEQ ID NO.3, PKKKRKV) is incorporated into the C-terminus of the Cas9 coding sequence (SEQ ID NO.2) to localize the expressed Cas9 to the cell nucleus to better exert gene editing activity. The above vector was synthesized by Beijing Sino-US Taihe Biotechnology Co., Ltd.

[0021] 2. Acquisition of Cas9 variants and cloning of pGAP-Cas9 recombinant vectors carrying Cas9 variants Cas9 was randomly mutated using Biolabs’ ready-to-use error-prone PCR kit (BTN101005) and pGAP-Cas9 vector as templates.

[0022] Error-prone PCR system (50 μL): 3 μL of 10× error-prone PCR Mix (enzyme included), 5 μL of primers CAS9-F / CAS9-R (AACTATCAAAACACAACTAGTGGATCCCCCGGGAAAAATGGAC / TAATTACATGACTCGAGAAGAGATCACACCTTCCTCTTC), 3 μL of error-prone PCR enhancer, 3 μL of dNTP for error-prone PCR, 3 μL of MnCl2 for error-prone PCR, and ultrapure water to 50 μL. Error-prone PCR system and procedure: 1 cycle of 94℃ pre-denaturation for 3 min; 1 cycle of 94℃ denaturation for 1 min, 60℃ annealing for 1 min, 72℃ extension for 4 min, 40 cycles; 72℃ final extension for 7 min for 1 cycle. The amplified Cas9 sequence was used as a template to repeat the above error-prone PCR process to accumulate mutation sites. Finally, the amplified sequence was purified and recovered by agarose gel electrophoresis.

[0023] By restriction endonuclease Spe Ⅰ and XOt Ⅰ Double restriction digestion of pGAP-Cas9 vector, agarose gel electrophoresis results are as follows Figure 2 As shown in A, well 1 is the vector control without enzyme digestion, and well 2 is the vector after enzyme digestion. The band in well 2 shows that pGAP-Cas9 was successfully digested, of which the upper band does not contain the Cas9 fragment (5263 bp) and the lower band contains the Cas9 fragment (4168 bp). The fragment obtained by error-prone PCR amplification was connected with the recovered fragment of the upper band of well 2 by seamless cloning and transformed into Escherichia coli competent cells Top10. Finally, the positive clones were identified by primers GAP-F / CYC-R (CGTCGCTGGCAATAATAGCG / CCTTCCTTTTCGGTTAGAGC) and sequenced to obtain a series of pGAP-Cas9 recombinant vectors carrying Cas9 variants. The results of colony PCR positive clone identification (partial) are shown in Figure 2 As shown in Figure B, a band of the target size (4204 bp) was successfully amplified, and a recombinant vector carrying mutation sites D276N, A421T, and A1184T was named pGAP-Cas9M24. The Sanger sequencing results (SEQ ID NO. 4) were compared as shown in Figure 4. Figure 3 shown.

[0024] 3. Construction of Cas9 / GS115 recombinant strain First, restriction endonucleases Nhe I am HIS4 The pGAP-Cas9 recombinant vector and the pGAP-Cas9M24 recombinant vector were linearized on the element, and then the linearized vector was transferred into the GS115 competent cells by electroporation. The linearized pGAP-Cas9 recombinant vector was integrated into the Pichia pastoris GS115 genome by the intracellular homologous end repair mechanism, and cultured at 30°C for 2-3 days in MD solid medium. Six clones on the MD plate were selected, and the growing clones were identified by colony PCR using primers GAP-F / CYC-R: (CGTCGCTGGCAATAATAGCG / CCTTCCTTTTCGGTTAGAGC), and sequenced for confirmation. The agarose gel electrophoresis results are shown in Figure 2. Figure 4 As shown, the target size band (4414 bp) was amplified. In the present invention, the recombinant strain in which pGAP-Cas9 is integrated into the yeast strain is named CRISPR-Cas9, and the recombinant strain in which pGAP-Cas9M24 is integrated into the yeast strain is named CRISPR-Cas9M24.

[0025] Example 2. Functional evaluation of CRISPR-Cas9 and CRISPR-Cas9M24 To verify the gene editing function of CRISPR-Cas9 and CRISPR-Cas9M24, we constructed four gRNAs targeting different PAM motifs.

[0026] 1. gRNA recombinant vector cloning pTEF (commercially available) is used as a gRNA expression vector and is kept in our laboratory. This vector carries a bleomycin resistance gene for transformation and screening of prokaryotic bacteria and yeast strains. The gRNA expression cassette is transcribed by the TEF promoter, which contains a restriction endonuclease Afl Ⅱ is used to add 20nt target sequence and gRNA scaffold. The present invention selects four target sites from the Pichia pastoris genome for gRNA construction ( Figure 5 ) to verify the functionality of CRISPR-Cas9 and CRISPR-Cas9M24.

[0027] (1) pTEF-GUT1-3 expression vector: from the Pichia pastoris genome PAS_Chr4_0783 The gene selects a sequence with a PAM motif of AGG (GTTGTTTGGTCCAAGAAGAC 412-431) The primers GUT1-3-F / GUT1-3-R (AGGACGAAACGAGTAAGCTCGTCTCAGATC GTTGTTTGGTCCAAGAAGAC / ATTTTAACTTGCTATTTCTAGCTCTAAAAC GTCTTCTTGGACCAAACAAC) with homology arms at both ends of the pTEF vector and the target sequence were synthesized, and the target fragment was obtained by primer overlap extension PCR.

[0028] (2) pTEF-GUT1-2 expression vector: from the Pichia pastoris genome PAS_Chr4_0783 The gene selected a sequence with a PAM motif of TGG (TGCAATTTCCTCAGCCAGGC 239-256 ) Primers GUT1-2-F / GUT1-2-R (AGGACGAAACGAGTAAGCTCGTCTCAGATC TGCAATTTCCTCAGCCAGGC / ATTTTAACTTGCTATTTCTAGCTCTAAAAC GCCTGGCTGAGGAAATTGCA) with homology arms at both ends of the pTEF vector and the target sequence were synthesized, and the target fragment was obtained by primer overlap extension PCR.

[0029] (3) pTEF-AC expression vector: from the Pichia pastoris genome PAS_chr1-1_0483 The gene selects a sequence with a PAM motif of CGG (ACACAACACACACACATTAG 2745-2764 ) Synthesize primers AC-F / AC-R (AGGACGAAACGAGTAAGCTCGTCTCAGATCACACAACACACACACATTAG / ATTTTAACTTGCTATTTCTAGCTCTAAAACCTAATGTGTGTGTGTTGTGT) with homology arms at both ends of the pTEF vector and the target sequence, and obtain the target fragment by primer overlap extension PCR.

[0030] (4) pTEF-H1 expression vector: from the Pichia pastoris genome PAS_chr1-4_0160 The gene selects a sequence with a PAM motif of GGG (GGCAGGAACACCCAGCATCA 1637-1656 ) Primers AC-F / AC-R (AGGACGAAACGAGTAAGCTCGTCTCAGATC GGCAGGAACACCCAGCATCA / ATTTTAACTTGCTATTTCTAGCTCTAAAAC TGATGCTGGGTGTTCCTGCC) with homology arms at both ends of the pTEF vector were synthesized, and the target fragment was obtained by primer overlap extension PCR.

[0031] pTEF vector was cleaved by restriction endonuclease Afl Ⅱ was linearized and purified. The above four amplified fragments were seamlessly cloned and transformed with the linearized vector, and the positive clones were identified and sequenced by primers gRNA-F / 3AOX (AGTAAGCTCGTCTCAGATCTTAAG / GCAAATGGCATTCTGACATCC) to obtain the correct recombinant vector. The structural diagrams of pTEF-GUT1-3, pTEF-GUT1-2, pTEF-AC and pTEF-H1 are shown in the figure. Figure 5 Table 1 shows the gRNA target sequences and PAM sequences for 4 different PAM motifs, all of which are 20 nt in length.

[0032] Table 1. gRNA target sequences and PAM sequences

[0033] Figure 6 This is the colony PCR identification picture after the above four gRNA recombinant vectors were constructed and transformed. The band size is correct (245bp). The Sanger sequencing results are as follows Figure 7 As shown, the recombinant vectors pTEF-GUT1-3, pTEF-GUT1-2, pTEF-AC, and pTEF-H1 were successfully constructed.

[0034] 2. Functional verification of CRISPR-Cas9 and CRISPR-Cas9M24 The four gRNAs were transferred into the recombinant strains containing CRISPR-Cas9 and CRISPR-Cas9M24 by electroporation, and positive clones were screened on YPDS Z+ solid plates. The growth of positive clones on the YPDS Z+ solid plates was counted by taking photos. Figure 8 This is a typical plate screening clone image. Fig. 9 The above results show that compared with CRISPR-Cas9, the number of positive clones screened by YPDS Z+ solid plate increased by about 2-11 times (560 vs 280, 2160 vs 188, 258 vs 65, 475 vs 268) in the CRISPR-Cas9M24 strain after the four gRNAs were transferred, which suggests that the gene editing system in the CRISPR-Cas9M24 strain may be more beneficial to the survival of yeast, which means that the Cas9 protein mutant Cas9M24 may be less toxic to yeast.

[0035] Subsequently, we picked 10 single clones from the YPDS Z+ solid plates after the four gRNAs were transferred into CRISPR-Cas9 and CRISPR-Cas9M24 to amplify the target gene containing the target sequence and sent it for Sanger sequencing. The Sanger sequencing results are shown in Figure 2. Fig.10 As shown in the figure, both CRISPR-Cas9 and CRISPR-Cas9M24 can cause base deletion or insertion in the target sequence. When the PAM motif is CGG and GGG, the gene editing efficiency of CRISPR-Cas9 and CRISPR-Cas9M24 is 90-100%, while when the PAM motif is AGG and TGG, the gene editing efficiency of CRISPR-Cas9M24 is as high as 100%, which is 10% higher than that of CRISPR-Cas9. In TGG, the deletion efficiency of CRISPR-Cas9M24 for the 4th base upstream of the 5' end of PAM is 20% higher than that of CRISPR-Cas9. The above results show that the CRISPR-Cas9M24 system has less toxicity and inhibition to yeast cells and is more suitable for genetic engineering operations in yeast cells.

[0036] Therefore, in Pichia pastoris, this Cas9 mutant exhibits better stability and compatibility. It can better adapt to the physiological environment of Pichia pastoris and work in conjunction with other biological molecules in the cell to achieve more efficient gene editing. The excellent performance of this Cas9 mutant in Pichia pastoris provides broad prospects for its application in biomanufacturing, metabolic engineering, drug development and other fields. For example, this mutant can be used to precisely edit the metabolic pathways of Pichia pastoris to increase the yield of specific compounds or optimize production conditions.

Claims

1. A Cas9 protein mutant, characterized in that: The Cas9 protein mutant is a mutant having D276N, A421T, and A1184T in the sequence of SEQ ID NO.

1.

2. A polynucleotide encoding the Cas9 protein mutant according to claim 1.

3. The polynucleotide according to claim 2, characterized in that The sequence of the polynucleotide is shown in SEQ ID NO.

4.

4. A vector expressing the Cas9 protein mutant according to claim 1, characterized in that: The vector contains the polynucleotide according to claim 2 or 3.

5. A method for gene editing using the vector according to claim 4, characterized in that: The method comprises the following steps: (1) transforming the vector of claim 4 into a host bacterium to obtain a recombinant host bacterium in which the vector is integrated into the genome; (2) constructing a vector containing a gRNA targeting the target gene in the host bacteria genome in step (1), and transforming the vector into the recombinant host bacteria obtained in step (1); (3) Cultivate the recombinant host bacteria obtained in step (2) and screen the target gene to obtain edited positive host bacteria.

6. The method according to claim 5, characterized in that The host bacteria in step (1) is yeast.

7. The method according to claim 6, characterized in that The yeast is the yeast GS115 strain.

8. The method according to claim 5, characterized in that In step (2), the PAM motif at the 3' end of the target gene is AGG or TGG.

9. The method according to claim 5, characterized in that The length of the gRNA target sequence in step (2) is 20 nt.

10. A gene editing kit, characterized in that: The kit includes a vector for expressing the Cas9 protein mutant according to claim 1, and a vector containing a gRNA targeting the target sequence of the target gene to be edited.

Citation Information

Patent Citations

  • Engineered crispr-cas9 nucleases

    CN108350449A

  • Evolved cas9 proteins for gene editing

    CN108699116A

  • Cas9 mutant for improving gene editing efficiency and application

    CN115960867A

  • CAS9 variants having non-canonical PAM specificities and uses thereof

    US20230021641A1

  • CAS9 variants having non-canonical PAM specificities and uses thereof

    WO2020041751A1